
41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists
<a href="https://news.google.com/rss/articles/CBMiwwJBVV95cUxPSHQ2T2JrbGNNNXFENWFFd2E4Sm9RdjZOLXZiSEkwRFl6T2Z1QXE4c3Y1N2xnLTYyR0hVYktwWkNoZHk1elRmeTA2Q3lxQ2EzVkZUZS1acmJfazdndDZ3MEx1dU5HN09Fa2t2NXdLeUh3OG0yekFhSk9qdDl1cWtSNFJnZy1TOEowMUlMRl83SlZXSFVNUWVDX2lLWXJUV2xvaXBKNHRkRUQ5R3ZwSG9TTmVWMkxrRDhGTkw1R2poWExZU0NYZ3RfX3liRnduWlJIVlFfdDZQLWtXekVYRTFGSHdGSmlkY2hEQm15bjRMSTdoRHBWWFFZWnZ4UjFzeXRWQk9wbmFEUGFIVVRVdjI2N3VRaEhJaXdEcEZXdGlmbXFWZXlleTdkeDRGQmtTZjZXd2tiWmRlajlvNW1fOGthSzl1VQ?oc=5" target="_blank">41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
